A groundbreaking study from Johns Hopkins University researchers has uncovered a critical connection between prediabetes, hypertension, and elevated heart failure risk through key biomarkers. Published in JAMA Cardiology on January 14, 2026, the research analyzes data from the SPRINT trial, revealing that adults with hypertension who also have prediabetes and subclinical signs of heart muscle damage or stress face up to a 10-fold increased risk of developing heart failure compared to those without these factors.
This finding underscores the importance of routine biomarker screening in at-risk populations, potentially transforming preventive cardiology. Led by senior author Justin Basile Echouffo Tcheugui, M.D., Ph.D., an associate professor at the Johns Hopkins University School of Medicine, the study highlights how metabolic disturbances in prediabetes amplify subclinical cardiac issues, paving the way for targeted interventions before overt heart failure emerges.
Understanding the Perfect Storm: Prediabetes, Hypertension, and Subclinical Heart Changes
Prediabetes, characterized by fasting blood glucose levels between 100 and 125 mg/dL, affects approximately 115 million U.S. adults as of 2026. It represents a precursor to type 2 diabetes, often accompanied by insulin resistance and metabolic inflammation that silently strains the cardiovascular system. Hypertension, or high blood pressure, impacts nearly 47% of American adults and is a leading modifiable risk factor for heart disease.
When combined, these conditions create a 'perfect storm' for heart failure. Subclinical myocardial injury refers to microscopic heart muscle damage without symptoms, while subclinical myocardial stress indicates strain on the heart's pumping ability. The Johns Hopkins study shows that in hypertensive adults, prediabetes exacerbates these hidden issues, leading to dramatically higher heart failure incidence.
Key Biomarkers: hs-cTnI and NT-proBNP Explained
High-sensitivity cardiac troponin I (hs-cTnI) is a protein released when heart muscle cells are damaged. In the study, levels ≥6 ng/L in men or ≥4 ng/L in women signaled subclinical injury. N-terminal pro-B-type natriuretic peptide (NT-proBNP), released by the heart in response to wall stress and volume overload, was elevated at ≥125 pg/mL, indicating subclinical stress. These biomarkers are detectable via standard blood tests, making them practical for clinical use.
Both predict heart failure effectively, with hs-cTnI reflecting acute or chronic myocyte necrosis and NT-proBNP signaling ventricular strain. Their combination with prediabetes status refines risk prediction far beyond traditional factors like age or cholesterol.
The SPRINT Trial Cohort and Study Design
Drawing from the Systolic Blood Pressure Intervention Trial (SPRINT), a landmark NIH-funded study launched in 2010, researchers examined 8,234 hypertensive adults aged 50+ (mean 68 years, 63% male) without diabetes or prior heart failure. Baseline data included fasting glucose and biomarkers; a subset had 12-month follow-ups.
Over a median 3.2 years, 122 developed heart failure. Cox proportional hazards models quantified risks, adjusting for confounders like age, sex, and BMI. This rigorous design ensures robust, real-world applicability.
Striking Results: Quantified Risks and Hazard Ratios
At baseline, 39.7% had prediabetes, 35.7% subclinical injury, and 43.6% stress. Those with prediabetes plus injury faced a hazard ratio (HR) of 4.20 (95% CI 2.31-7.63) for heart failure versus normoglycemia without injury; with stress, HR 5.20 (2.52-10.70)—overall ~10-fold risk.
- Prediabetes + injury: HR 4.20
- Prediabetes + stress: HR 5.20
- No prediabetes + injury: HR 3.28
- No prediabetes + stress: HR 3.78
Longitudinally, a ≥25% rise in hs-cTnI with prediabetes yielded HR 3.05 (1.58-5.88); NT-proBNP HR 2.39 (1.28-4.46).
Clinical Implications: From Screening to Intervention
These biomarkers enable precise risk stratification in primary care, identifying high-risk prediabetic hypertensives for aggressive management. Echouffo Tcheugui notes: "Using heart failure biomarkers, we can identify and treat these patients who have a much higher risk of cardiovascular disease."Johns Hopkins press release
Integration into routine checkups could prevent thousands of cases annually, reducing U.S. heart failure prevalence (~6.5 million) and costs ($46 billion yearly).
U.S. Burden: Prevalence, Disparities, and Economic Toll
Heart failure affects 1.8% of U.S. adults, with cardiovascular disease causing 919,000 deaths in 2023. Prediabetes (115M) and hypertension (47%) overlap significantly, driving epidemics. Healthcare costs for heart failure exceed $32 billion direct annually, amplified by comorbidities—diabetes alone adds 34% to expenditures.
- Prediabetes: 115M adults
- Hypertension: ~120M
- HF costs: $32B direct + $14B indirect
Disparities hit low-income and minority groups hardest, per JACC 2026 stats.
Prevention Roadmap: Lifestyle, Meds, and Monitoring per AHA/ACC
AHA/ACC guidelines emphasize lifestyle: Mediterranean diet, 150min weekly exercise, BP <130/80 mmHg, glucose control. For prediabetes, metformin or GLP-1 agonists; SGLT2 inhibitors for HF prevention in hypertensives.
- Weight loss: 5-10% reduces risk
- BP meds: ACEIs/ARBs first-line
- Biomarker screening: Annual hs-cTnI/NT-proBNP
- Smoking cessation, limit alcohol
Future Directions: Expanding Biomarker Research at Institutions like Johns Hopkins
JHU's Ciccarone Center leads in preventive cardiology. Upcoming trials may validate multi-biomarker panels for personalized risk scores, integrating AI for prediction. Longitudinal studies on interventions in prediabetic hypertensives are needed.
This positions universities as hubs for translational research, training fellows in biomarker-driven care.
Careers in Cardiology Research: Opportunities at Johns Hopkins and Beyond
The study exemplifies demand for experts in cardiovascular epidemiology. JHU offers research assistantships in DOM Cardiology, fellowships, and faculty roles. Explore higher ed faculty jobs or academic CV tips for advancing in preventive cardiology.
Rate professors via Rate My Professor for insights into JHU's programs.
Photo by Marek Studzinski on Unsplash
Conclusion: Actionable Insights for a Healthier Future
The Johns Hopkins heart failure risk biomarkers study empowers proactive care, potentially averting millions in costs and lives lost. Academic institutions drive these advances—pursue higher ed jobs, university jobs, or rate your professors. For career advice, visit higher ed career advice.
